Navigation Links
Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
Date:3/23/2009

CONSHOHOCKEN, PA and VANCOUVER, BC, March 23 /PRNewswire/ - Neuromed Pharmaceuticals, Inc. today announced positive results of a pivotal phase 3 clinical trial of its lead investigational drug, Exalgo (hydromorphone HCl) Extended-Release Tablets (CII) (previously NMED-1077 and OROS(R) Hydromorphone). The trial met its primary efficacy endpoint, the mean change from baseline to week 12 (or last visit) of average weekly pain intensity scores, and the results were statistically significant (p(less than)0.0001). The primary efficacy endpoint was agreed upon with the U.S. Food and Drug Administration (FDA) during the Special Protocol Assessment (SPA) process(1).

Neuromed is seeking approval of Exalgo in the U.S. for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. The FDA has stated in an Approvable Letter that one successful adequate and well-controlled clinical trial will be needed to support approval of Exalgo.

"The successful completion of our pivotal phase 3 clinical trial brings us closer to reaching our goal of providing an effective once-daily pain medication for opioid tolerant patients with moderate to severe pain requiring around-the-clock opioid analgesia for an extended period of time," said Dr. Christopher Gallen, President and Chief Executive Officer of Neuromed. "We have now successfully completed a major milestone of our development plan and are on schedule to submit our FDA application planned for the second quarter of 2009."

Martin E. Hale, M.D., Principal Investigator of the pivotal phase 3 clinical trial stated, "Hydromorphone is a clinically proven analgesic that is not currently available in a long acting oral formulation. Exalgo, if approved, will provide an additional option in the treatment of chronic moderate to severe pain in opioid tolerant patients."

Study Design and Results


'/>"/>
SOURCE Neuromed Pharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
2. Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
3. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
4. Nfocus Neuromedical Announces Acquisition of StarFire Medical
5. Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Line: Patients with advanced laryngeal cancer appear to ... surgery than nonsurgical chemoradiation. , Author: Uchechukwu C. ... Medicine at Mount Sinai, New York, and colleagues. ... laryngeal cancer are diagnosed each year and squamous ... these tumors. Prior to 1991, total surgical removal ...
(Date:8/21/2014)... Improv performers from Fun House Theatre and ... Silverado Turtle Creek memory care community in Dallas. The ... from ages 10 to 16, delivers a groundbreaking and ... The troupe's philosophy is that improv is based on ... touch audiences regardless of their circumstance — including bringing ...
(Date:8/21/2014)... the environmental source of fungal infections that have been ... literally grows on trees. , The discovery is based ... spent the summer gathering soil and tree samples from ... the fungus named Cryptococcus gattii (CRIP-to-cock-us ... number of species including C. gattii , causes ...
(Date:8/21/2014)... California (PRWEB) August 21, 2014 The ... initial plans for entertainment and programming for its inaugural ... On Sunday, October 12, 2014, from 11 a.m. to ... closed to all cars and the downtown will be ... activities, curated by Community Arts Resources (CARS), for all ...
(Date:8/21/2014)... 2014 (HealthDay News) -- Not only is eating better and ... hundreds of health-care dollars a year, a new study finds. ... public health sciences at Wake Forest Baptist Medical Center in ... type 2 diabetes patients. Participants ranged in ... either an intensive "lifestyle change program" focused on diet and ...
Breaking Medicine News(10 mins):Health News:Surgery associated with better survival for patients with advanced laryngeal cancer 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2
... brought havoc to human community by killing around 50 million ... lethal and the affected bodies exhibited a strange type of ... counter productive to the person affected. ,American researchers ... monkeys. The lungs of the monkeys were damaged within a ...
... create a calendar-like printout every time a prescription is ... associate dean, who wanted to reduce consumer confusion with ... knowing which pill is which, when to take what ... ,'The idea came to me when a relative ...
... a process for rapidly and efficiently separating blood plasma at ... //to do blood tests without sending samples to a laboratory. ... causes tea leaves to accumulate at the center of the ... Einstein in the 1920s. ,Separating blood plasma from ...
... involved in a worldwide research have come up with a ... gel is expected to evolve into a powerful new protection ... would be 95% efficient. ,Brazilian scientists, who ... using microbicides , assure the gel will be on the ...
... cancer is the fourth leading cause of cancer death in ... from the disease this year.// ,Pancreatic cancer is ... about what causes it. One established risk factor in pancreatic ... obesity, diabetes type 2 and insulin resistance. In a new ...
... fatal, at the hands of stomach cancer, according to experts. ... rest a mystery of 200 years, // regarding the cause ... recent theory, running since the 1961 discovery of arsenic in ... was due to arsenic poisoning. ,Publishing results in the ...
Cached Medicine News:Health News:New Software to Help Patients 2Health News:Einstein's Tea Leaves Inspire New Blood Separation Technique 2Health News:Link Found Between Periodontal Disease and Pancreatic Cancer 2Health News:Mighty Conqueror Felled by Stomach Cancer 2
(Date:8/21/2014)... 2014 BreedIT Corp., (OTCQB: ... exclusive worldwide license holder and distributor of highly ... researchers, today is pleased to announce the formation ... Ltd, a leading Israeli medical Cannabis breeder. ... new breeds of medical Cannabis to meet the ...
(Date:8/21/2014)... FAIRFAX, Va. , Aug. 21, 2014 /PRNewswire/ ... real-time quality and Manufacturing Intelligence , today ... Intelligence Conference. The event will be held Oct. ... Mile, and is designed to showcase the necessity ... use of metrics and Manufacturing Intelligence to gain ...
(Date:8/21/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... and consideration payable in connection with its previously announced cash ... for (1) any and all of its 6.250% Senior Notes ... to a maximum amount of its 6.125% Senior Notes due ... due 2017 (collectively, the "Maximum Tender Offer Notes" and together ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
... ST. LOUIS, Nov. 14, 2011 Express Scripts, Inc. ... wholly owned subsidiary, Aristotle Holding, Inc., a Delaware corporation ... of a benchmark amount.  The net proceeds from the ... the cash consideration payable to stockholders of Medco Health ...
... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced ... observations from previous clinical trials of Zerenex™ (ferric citrate) ... during the American Society of Nephrology (ASN) Kidney Week ... oral, ferric iron-based drug candidate, is currently in Phase ...
Cached Medicine Technology:Express Scripts, Inc. Launches Senior Notes Offering 2Express Scripts, Inc. Launches Senior Notes Offering 3Express Scripts, Inc. Launches Senior Notes Offering 4Express Scripts, Inc. Launches Senior Notes Offering 5Express Scripts, Inc. Launches Senior Notes Offering 6Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 2Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 3Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: